Comparative thrombotic risk associated with CALR1, CALR2, and JAK2 V617F mutations in essential thrombocythemia

被引：1
|
作者：
Neupane, Niraj [1 ]
Low, Soon K. [2 ]
Kharel, Himal [1 ]
Bhattarai, Sanket [3 ]
Thapa, Sangharsha [4 ]
Mahmoud, Amir [1 ]
Pokhrel, Nishant B. [5 ]
Din, Mohammad Ammad Ud [6 ]
Kouides, Peter [7 ]
机构：
[1] Rochester Gen Hosp, Dept Internal Med, Rochester, NY 14621 USA
[2] Med Coll Wisconsin, Dept Hematol & Oncol, Milwaukee, WI USA
[3] Mayo Clin, Rochester, MN USA
[4] New York Med Coll, Westchester Med Ctr, Dept med, Westchester, NY USA
[5] Norwalk Hosp, Dept Internal Med, Norwalk, CT USA
[6] H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol & Oncol, Tampa, FL USA
[7] Rochester Gen Hosp, Lipson Canc Inst, Dept Hematol, Rochester, NY USA
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 99卷 / 01期
关键词：
PROGNOSIS; SUBTYPES;
D O I：
10.1002/ajh.27148
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E26 / E28
页数：3
相关论文
共 19 条
  • [1] CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
    Mikic, Tanja Belcic
    Pajic, Tadej
    Sever, Matjaz
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [2] Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2V617F or MPL mutations
    Li, Ning
    Yao, Qiu-Mei
    Gale, Robert Peter
    Li, Jin-Lan
    Li, Ling-Di
    Zhao, Xiao-Su
    Jiang, Hao
    Jiang, Qian
    Jiang, Bin
    Shi, Hong-Xia
    Chen, Shan-Shan
    Liu, Kai-Yan
    Huang, Xiao-Jun
    Ruan, Guo-Rui
    LEUKEMIA RESEARCH, 2015, 39 (05) : 510 - 514
  • [3] JAK2V617F, CALR, and MPL Mutations and Bone Marrow Histology in Patients with Essential Thrombocythaemia
    Pich, Achille
    Riera, Ludovica
    di Celle, Paola Francia
    Beggiato, Eloise
    Benevolo, Giulia
    Godio, Laura
    ACTA HAEMATOLOGICA, 2018, 140 (04) : 234 - 239
  • [4] Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms
    Lilleskare, Susanne
    Vorland, Marta
    Vo, Anh Khoi
    Aarsand, Aasne K.
    Reikvam, Hakon
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2023, 83 (01): : 3 - 7
  • [5] Absence of JAK2 V617F mutation in thalassemia intermedia patients
    Taher, Ali
    Shammaa, Dina
    Bazarbachi, Ali
    Itani, Doha
    Zaatari, Ghazi
    Greige, Layal
    Otrock, Zaher K.
    Mahfouz, Rami A. R.
    MOLECULAR BIOLOGY REPORTS, 2009, 36 (06) : 1555 - 1557
  • [6] Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis
    Saki, N.
    Shirzad, R.
    Rahim, F.
    Malehi, A. Saki
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (07): : 874 - 883
  • [7] Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis
    N. Saki
    R. Shirzad
    F. Rahim
    A. Saki Malehi
    Clinical and Translational Oncology, 2017, 19 : 874 - 883
  • [8] Expression of CD markers in JAK2(V617F) positive myeloproliferative neoplasms: Prognostic significance
    Shahrabi, Saeid
    Ehsanpour, Ali
    Heidary, Somayyeh
    Shahjahani, Mohammad
    Behzad, Masumeh Maleki
    ONCOLOGY REVIEWS, 2018, 12 (02) : 109 - 120
  • [9] JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
    Tefferi, A.
    Lasho, T. L.
    Patnaik, M. M.
    Finke, C. M.
    Hussein, K.
    Hogan, W. J.
    Elliott, M. A.
    Litzow, M. R.
    Hanson, C. A.
    Pardanani, A.
    LEUKEMIA, 2010, 24 (01) : 105 - 109
  • [10] JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival
    A Tefferi
    T L Lasho
    M M Patnaik
    C M Finke
    K Hussein
    W J Hogan
    M A Elliott
    M R Litzow
    C A Hanson
    A Pardanani
    Leukemia, 2010, 24 : 105 - 109
12